INTUITIVE ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS (Form 8-K)

INTUITIVE ANNOUNCES PRELIMINARY

FOURTH QUARTER AND FULL YEAR 2025 RESULTS

SUNNYVALE, CALIF. January 14, 2026 - Intuitive (the "Company") (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Financial and Operational Highlights

•Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%. Average da Vinci system utilization increased 4% in the fourth quarter of 2025 as compared with the fourth quarter of 2024, primarily driven by adoption of da Vinci 5 in the U.S. and continued growth in utilization in OUS markets.

•Full year 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 19% compared with 2024. Da Vinci procedures grew approximately 18% and Ion procedures grew approximately 51%. The Company expects worldwide da Vinci procedures to increase approximately 13% to 15% in 2026 as compared with 2025.

•During the fourth quarter of 2025, the Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 in the fourth quarter of 2024. During the fourth quarter of 2025, the Company placed 42 Ion endoluminal systems, compared with 69 in the fourth quarter of 2024.

•During 2025, the Company placed 1,721 da Vinci surgical systems, compared with 1,526 systems in 2024. The 2025 da Vinci surgical system placements included 870 da Vinci 5 systems, compared with 362 in 2024. During 2025, the Company placed 195 Ion endoluminal systems, compared with 271 in 2024.

•Preliminary fourth quarter 2025 revenue of approximately $2.87 billion increased by 19% compared with $2.41 billion in the fourth quarter of 2024. Preliminary 2025 revenue of approximately $10.06 billion increased by 21% compared with $8.35 billion in 2024.

•Fourth quarter 2025 expenses included a $70 million contribution to the Intuitive Foundation compared to a $45 million contribution to the Intuitive Foundation in the fourth quarter of 2024.

Preliminary Results

The Company expects fourth quarter 2025 revenue of approximately $2.87 billion, an increase of 19% compared with $2.41 billion in the fourth quarter of 2024. The higher fourth quarter revenue was driven by growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of systems. The Company expects 2025 revenue of approximately $10.06 billion, an increase of 21% compared with $8.35 billion in 2024. The unaudited results in this press release are preliminary and subject to the completion of the Company's final closing procedures and annual independent audit and, therefore, are subject to adjustment.

Preliminary fourth quarter 2025 instruments and accessories revenue increased by 17% to approximately $1.66 billion, compared with $1.41 billion in the fourth quarter of 2024, primarily driven by approximately 18% growth in worldwide procedure volume. Preliminary full year 2025 instruments and accessories revenue increased by 19% to approximately $6.02 billion, compared with $5.08 billion for 2024, primarily driven by approximately 19% growth in worldwide procedure volume.

Fourth quarter 2025 da Vinci procedures increased approximately 17% compared with the fourth quarter of 2024. Overall, in 2025, approximately 3,153,000 surgical procedures were performed with da Vinci surgical systems, an increase of approximately 18% compared with approximately 2,683,000 surgical procedures performed with da

Page 1 of 3

Vinci surgical systems in 2024. The growth in the Company's overall da Vinci procedure volume in 2025 was largely attributable to 18% growth in United States ("U.S.") general surgery procedures as well as 23% growth in total da Vinci procedures performed outside of the U.S. ("OUS") across a broad set of procedure specialties. The Company expects worldwide da Vinci procedures to increase approximately 13% to 15% in 2026.

Preliminary fourth quarter 2025 systems revenue was approximately $786 million, compared with $655 million in the fourth quarter of 2024. Higher systems revenue reflected increased da Vinci system placements, a higher lease installed base, and higher da Vinci system average selling prices compared with the fourth quarter of 2024. Preliminary full year 2025 systems revenue was approximately $2.47 billion, compared with $1.97 billion for 2024.

The Company placed 532 da Vinci surgical systems, of which 303 were da Vinci 5 systems, in the fourth quarter of 2025, compared with 493 systems, of which 174 were da Vinci 5 systems, in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 250 systems placed under operating lease arrangements, of which 150 systems were placed under usage-based operating lease arrangements, compared with 222 systems placed under operating lease arrangements, of which 140 systems were placed under usage-based operating lease arrangements in the fourth quarter of 2024.

The Company placed 1,721 da Vinci surgical systems, of which 870 were da Vinci 5 systems, in 2025, compared with 1,526 systems, of which 362 were da Vinci 5 systems, in 2024. The 2025 da Vinci surgical system placements included 872 systems placed under operating lease arrangements, of which 496 systems were placed under usage-based operating lease arrangements, compared with 776 systems placed under operating lease arrangements, of which 467 systems were placed under usage-based operating lease arrangements in 2024.

Commenting on the announcement, Intuitive CEO Dave Rosa said, "We are pleased with our strong performance in the final quarter of 2025 and the full year. In 2025, we saw increased adoption and utilization of our surgical platforms, expanded product clearances and indications for use across geographies, and more than 3.1 million da Vinci procedures performed. As always, we remain focused on delivering the goals we share with our customers, centered on improving patient care and outcomes."

Additional unaudited preliminary revenue and procedure information has been posted to the Investor Relations section of the Intuitive website at: https://isrg.gcs-web.com/.

The Company is scheduled to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 9:00 a.m. PST. The Company is scheduled to report its fourth quarter 2025 results during a conference call on January 22, 2026, at which point the Company will discuss the 2025 financial results in more detail. Dial-in and webcast access information for both of these events are also available in the Investor Relations section of the Intuitive website.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owners. See www.intuitive.com/trademarks.

For more information, please visit the Company's website at www.intuitive.com.

Page 2 of 3